Addiction is a hijacked reward system. The brain has a circuit that’s supposed to make you chase food, sex, novelty, connection, the things that kept the species going. Drugs and alcohol short-circuit that circuit. They flood the dopamine pathway with a signal louder than anything food or a kiss or a paycheck ever produced, and the brain quietly reweights its entire priority list around getting that signal again. After enough exposure the rewiring is real and structural. It’s a thing you can see on imaging.
People are willing to hear “your brain got rewired.” The harder thing I have to say in clinic over and over is that the rewiring doesn’t undo the next thing you do. The biology is real and you still have to pick up the phone. Both are true. Holding both at the same time is most of recovery.
The other thing nobody tells you upfront: addiction almost never travels alone. The patient who walks in for help with drinking is, most of the time, also depressed, also anxious, also carrying trauma they haven’t named yet. Treating the substance without treating what’s underneath is a recipe for a relapse you could’ve predicted in week six.
The MAT landscape, drug by drug
Medication-assisted treatment is the part of addiction medicine that’s changed the most in the last twenty years, and the part most patients still walk in confused about. Quick tour of what exists and what it’s for.
For opioid use disorder there are three real options. Buprenorphine, usually prescribed as Suboxone (buprenorphine plus naloxone), is a partial agonist at the opioid receptor. It takes the edge off withdrawal, kills the craving, and has a ceiling effect that makes overdose much harder. Typical dosing lands between 8 and 24 mg a day. Methadone is a full agonist, more powerful, dispensed daily through a federally regulated clinic, still the right answer for some patients, especially people on high-dose fentanyl who don’t get full coverage on buprenorphine. Naltrexone, given as the monthly Vivitrol injection, works the opposite way. It blocks the receptor entirely. No high if you use. The trick with Vivitrol is you have to be fully detoxed before the first shot, which is the part that knocks a lot of people out of the running.
For alcohol use disorder the menu is different. Naltrexone again, oral or injectable, takes the reward out of drinking for most people who respond. Acamprosate (Campral) is the other first-line option, dosed three times daily, working on the glutamate side of the post-withdrawal brain and helping with the long, low-grade misery that follows the first month dry. Disulfiram (Antabuse) is the old-school one. It doesn’t reduce craving, it just makes you violently sick if you drink on it. Works for the narrow group of patients who want an external brake and will take the pill every morning.
Stimulant use disorder, the cocaine and meth side, still doesn’t have a great medication answer. Bupropion has some evidence. Contingency management (the clinical term for paying people small amounts to test clean) is the best-supported intervention we have for stimulants, and it’s almost never available because insurance won’t pay for it. That’s the state of the field.
Medication is what buys you the room to do the rest of the work.
Harm reduction vs. abstinence, the conversation people don’t want to have
There’s a long-running ideological fight in addiction medicine between the abstinence camp and the harm-reduction camp. The abstinence camp says the goal is zero substance, period, and anything less is enabling. The harm-reduction camp says the goal is fewer overdoses, fewer infections, fewer dead patients, and we’ll take whatever movement in that direction we can get. Twelve-step programs sit firmly in the first camp. Most modern addiction psychiatry has moved toward the second, or at least toward something pragmatic in the middle.
My take is that the framing is a false choice for most patients. The patient sitting across from me wants to drink less or use less or not die. Whether the goal is “zero” or “way less than now” is something I negotiate with them, not a flag I plant on day one. I had a woman come in last winter who’d been drinking a bottle of wine a night for fifteen years. She didn’t want sober. She wanted two glasses on Friday and Saturday. We tried naltrexone with Sinclair-method dosing, an hour before she drank, and at the six-month mark she was holding her stated goal and her liver enzymes had come back to normal. AA would call that an incomplete win. I’d call it a real one.
For opioids, the calculus is different. Fentanyl is in everything and the cost of a relapse is sometimes a body bag, so I push harder toward stable MAT and away from anything that involves chipping. For alcohol, where the acute danger curve is gentler (with the real exception of severe withdrawal, which can kill you and needs medical detox), there’s more room to negotiate.
What psychiatry does, what rehab does, what they aren’t
Patients show up confused about the levels of care, so here’s the rough map.
Meds + check-ins
Where you get the Suboxone, the Vivitrol, the naltrexone, the antidepressant for the depression underneath. Weekly early, then spacing out. Doesn’t replace a therapist or a group.
Intensive outpatient
Three sessions a week, three hours each, for about 8 to 12 weeks. Group plus individual. You sleep at home. The sweet spot for most working adults who need structure but don’t need a bed.
Rehab
28 to 90 days inpatient. For people whose home environment is the trigger, or whose withdrawal needs medical management, or who’ve tried outpatient and the wheels keep coming off. Expensive. Sometimes the only thing that works.
A psychiatrist managing the medication is one piece. A weekly therapist who knows addiction is another. A group, whether AA, SMART Recovery, Refuge Recovery, or an IOP-attached group, is a third. Most patients who actually stay in recovery have some version of all three running at once for the first year. The ones who try it on meds alone, or meetings alone, or willpower alone, are the ones I see coming back through the door at month nine.
The comorbidity reality, and why it ruins single-track treatment
If you pull the chart of any hundred patients with substance use disorder, somewhere around 50 to 70 percent will have at least one other psychiatric diagnosis. Major depression. Generalized anxiety. PTSD. Bipolar. ADHD, especially in the stimulant-use folks. The mood disorder was often there first, since adolescence, and the substance was the patient’s attempt to medicate it themselves.
I had a guy a couple years back, mid-thirties, opioids for eight years. We got him on buprenorphine and he did fine on the drug side. Six months in he was still miserable. Not craving, not using, just deeply unhappy in a way that wasn’t going to fix itself with more meetings. Turned out he’d been carrying untreated PTSD from a childhood nobody had ever asked him about, and the opioids had been the thing that made it shut up. We added an SSRI, got him in front of an EMDR therapist, and recovery started actually feeling like recovery instead of sober suffering.
That pattern, the patient who got dry and then realized why they were drinking, is one of the most common things I see. The substance was the lid on the box. Take the lid off and whatever was in the box is right there, often louder than before. Anyone who treats addiction without also treating the depression, the anxiety, the trauma, is doing half the job and wondering why the relapse rate looks the way it does.
What to actually do this week
If any of this lands, the next move is one phone call. To a psychiatrist who does MAT, to a primary care doc comfortable prescribing buprenorphine (more of them are than were five years ago), to an IOP intake line, to SAMHSA’s helpline (1-800-662-4357, free, 24 hours). Pick the one that takes the least courage and do that one.
The hardest day of getting better is almost always the day before the first appointment. Most of my patients, looking back, can’t tell me what they were so afraid of. They can tell me they almost didn’t show.